Navigation Links
Smith & Nephew Announce the New RENASYS EZ(TM) System for Negative Pressure Wound Therapy

ST. PETERSBURG, Fla., Feb. 24 /PRNewswire-FirstCall/ -- Smith & Nephew's Advanced Wound Management division (LSE: SN; NYSE: SNN) today announced the U.S. launch of its new RENASYS(TM) EZ Negative Pressure Wound Therapy (NPWT) system, designed to address the needs of wound care professionals and patients, and allow clinicians to exercise their own best clinical judgment in NPWT with confidence. Smith & Nephew will preview the RENASYS(TM) EZ at the American Academy of Orthopaedic Surgeons Annual Meeting in Las Vegas, and will introduce it in March 2009.


Smith & Nephew designed the RENASYS(TM) EZ based on customer insights to improve the NPWT experience, focusing on greater ease-of-use and patient comfort across the full range of wound types. RENASYS(TM) EZ allows clinicians to use variable pressure control, enables clinicians to treat surgical, traumatic or chronic wounds according to the individual needs of the patient and the characteristics of the patient's wound. RENASYS(TM) EZ can be used with both the foam and gauze wound interfaces, allowing for broader therapy selection from a single supplier.

"Smith & Nephew asked clinicians and administrators worldwide what they wanted in a NPWT system," said Joe Woody, President, Smith & Nephew Advanced Wound Management. "Their answer? A system that delivers all the clinical benefits of NPWT while improving performance in patient comfort, ease of use, and cost-effectiveness. We believe that RENASYS(TM) EZ more than meets these needs and will play an important, growing role in the NPWT marketplace. With United Hospital Services and Apria Healthcare as our partners, we have the largest NPWT distribution channel in the U.S. and can deliver and support NPWT systems wherever clinicians and patients may need them."

Dr. Raymond Dunn, Chairman of Plastic Surgery, University of Massachusetts, said, "Negative pressure has given us another tool to manage difficult wounds. The new devices and range of wound interfaces that Smith & Nephew now offer provides clinicians with greater choice for different types of clinical wound problems. Smith & Nephew's leadership in this area will greatly facilitate additional innovation and research needed to improve patient outcomes and create greater economic value for the healthcare system."

RENASYS(TM) EZ Features & Functions

In addition to a simple control that varies pressure from 40 to 200 mmHg and the ability to use both foam and gauze dressings, Smith & Nephew designed RENASYS(TM) EZ with additional features that enhance the patient experience and facilitate its ease of use.

  • An intuitive design and quick-click connectors can help reduce the risk of error.
  • Multiple safety alarms and a patient lock-out feature alert clinicians to changes in pressure status or pump function.
  • The RENASYS(TM) EZ battery runs for up to 40 hours and charges in three hours.
  • A convenient IV pole and bed mounts reduce the system's footprint at the patient's bedside.
  • The system weighs only 7.4 lbs, reducing stress on the caregiver.

"We conducted the clinical in-market evaluation of the RENASYS(TM) EZ at University of Massachusetts," said Dr. Dunn. "We used the RENASYS(TM) EZ to treat a wide range of acute, chronic and peri-operative wounds. The study showed improved outcomes in the healing of skin grafts, including grafts for very complex wounds."

Promoting Choice in NPWT

Smith & Nephew introduced small, medium and large RENASYS(TM) F Foam Dressing Kits in December 2008 to provide clinicians with access to foam and gauze wound interfaces from a single NPWT device manufacturer. With the extra-large (43x30x3 cm) foam dressing kit due in March 2009, Smith & Nephew will offer the most comprehensive range of foam- and gauze-based dressing kits available in the marketplace.

"Foam may be cut easily to fit a patient's wound that has a regular contour, such as surgical dehiscence or abdominal wound," said Robin Carlstein, Senior Vice President of Advanced Wound Devices at Smith & Nephew. "For pain-sensitive patients or patients with shallow or irregular wounds, gauze may be a better choice for the wound bed. We want the clinician to be able to select the best wound interface based on the patient's needs, the wound, or the particular care setting."

Leadership in Wound Care

"True innovation in medical technology should improve patient outcomes and lower costs to the healthcare system," added Mr. Woody. "Smith & Nephew has been the innovative leader in wound care for over 150 years. We continually challenge ourselves to understand the critical issues faced by our customers and deliver products and services that add value to their clinical practice and healthcare institutions. We are the only company to provide a total wound management solution with a broad portfolio of great products. We are very excited about the future of our new NPWT solution."

Smith & Nephew will demonstrate the RENASYS(TM) EZ's efficacy, flexibility and ease of use at Booth 3211 and Booth 2817 of the American Academy of Orthopaedic Surgeons Annual Meeting. The meeting will be held at the Venetian/Sands EXPO in Las Vegas from February 25 to 29, 2009.

For more information regarding Smith & Nephew's solutions for NPWT, please visit

    Steve DiMattia +1 646 201 5445
    Managing Director
    EVC Group, Inc.

    Investors and Analysts
    Liz Hewitt +44 (0)20 7401 7646
    Group Director Corporate Affairs
    Smith & Nephew

    Other Inquiries
    Robin Carlstein +727 300 3726
    Global Senior Vice President
    Smith & Nephew Advanced Wound Management

About Smith & Nephew

Smith & Nephew is a global medical technology business, specializing in Orthopaedics, including Reconstruction, Trauma and Clinical Therapies; Endoscopy and Advanced Wound Management. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.

Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2008 were $3.8 billion.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding expected revenue growth and trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation, claims and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.

All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

SOURCE Smith & Nephew
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Activplant Corporation Announces Global Agreement with GlaxoSmithKline
2. U.S. Court of Appeals Rules That Smith & Nephew Does Not Infringe KCI Patents
3. Smith & Nephew Announces Agreement with the OREF Regarding Grants to Support Research and Education in Orthopaedics
4. Smithfield Foods Lean Generation(R) Deli Partnership with National Breast Cancer Foundation Celebrates $135,000 Contribution
5. GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer
6. Houlihan Smith Arranges Equity Investment Into Tri-Tech Health, LLC
7. Orthopaedic Surgeon Kevin Smith, MD, Joins Northwest Hospital & Medical Center and The Sports Medicine Clinic
8. GlaxoSmithKlines Drug Will Become New Clinical Gold Standard by 2012 for the Treatment of Relapsed/Refractory CLL
9. GlaxoSmithKline Awards Ten Area Healthcare Nonprofits with $40,000 Each in Funding
10. Smith & Nephew Advanced Wound Management Comments on Temporary Injunction in United Kingdom
11. GlaxoSmithKline and Dynavax Announce Worldwide Strategic Alliance : – Developing First-in-Class Endosomal TLR Inhibitors for Autoimmune and Inflammatory Diseases –
Post Your Comments:
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps , official ... NH to direct high-performance kids yoga training. ChildLight Yoga Studio is centrally situated in ... from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We are ...
(Date:2/5/2016)... ... ... Give To Cure today announced that it is working with ... Cure’s campaign that is crowdfunding clinical trials to help find cures faster for Alzheimer’s ... smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among users. , ...
(Date:2/5/2016)... ... ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental Health ... need. The event is scheduled to take place on February 27, 2016 from 9am ... care to community members in need. Each patient will be given the opportunity to ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the ... a dream. A hallmark feature of patients with eating disorders is significant self-criticism, and ... disorder behaviors and obsessions are regarded as maladaptive means for coping with this unease, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Calls Blacklist has just been updated by ... design and the developer has fixed known bugs within the app. Calls Blacklist allows ... phone while not consuming any of their device’s battery power or memory. It provides ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 Wegener ... Global Markets Direct,s, ,Wegener Polyangiitis - Pipeline ... Wegener Polyangiitis,s therapeutic pipeline. This report provides ... Polyangiitis, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
(Date:2/4/2016)... 4, 2016 Frontier Pharma: Chronic Obstructive ... Innovation Chronic Obstructive Pulmonary Disease ... inflammation of the airways and lungs. Persistent breathing ... the disease one of the leading causes of ... the world. COPD is linked to cumulative exposure ...
(Date:2/4/2016)... In response to the opioid abuse epidemic, today ... Medical Products and Tobacco, along with other FDA leaders, called ... to opioid medications. The plan will focus on policies aimed ... access to effective relief. --> ... the risk-benefit paradigm for opioids and ensure that the agency ...
Breaking Medicine Technology: